%0 Journal Article
%T Prospective Evaluation of p24 Antigen and HIV-1 Protease Assays at 6 Months and 12 Months Initiation of Antiretroviral Therapy in HIV Infected Participants at Federal Medical Center, Lokoja, Nigeria
%A Isaac P Emeje
%A Charles C Onyenekwe
%A Nkiruka R Ukibe
%A Joseph E Ahaneku
%J Archives of Pharmacy Practice
%@ 2320-5210
%D 2019
%V 10
%N 2
%P 72-80
%X Background: This was a cross-sectional study designed to evaluate the potential use of p24 antigen and HIV-1 protease assays in treatment monitoring of HIV-1 infection at Federal Medical Center, Lokoja Nigeria. Materials and Methods: 154 participants aged 18-64 years were randomly recruited. 40 (group A) participants on efavirenz, Lamivudine, and tenofovir, 35 (group B) participants on nevirapine, lamivudine, and zidovudine served as a test, while 79 (group C) participants not antiretroviral therapy (ART) served as control. Results: P24 antigen, HIV-1 protease and viral load were significantly decreased in test participants than in control participants (f=14.59, p=0.002), (f=22.9, p=0.005) and (f=117.541, p=0.001 respectively). Antigenic markers in test participants with 6 months of therapy were significantly higher than 12 months of therapy (P
%U https://archivepp.com/article/prospective-evaluation-of-p24-antigen-and-hiv-1-protease-assays-at-6-months-and-12-months-initiation-of-antiretroviral-therapy-in-hiv-infected-participants-at-federal-medical-center-lokoja-ni